INSMED INCORPORATED (NASDAQ:INSM) Files An 8-K Regulation FD Disclosure

INSMED INCORPORATED (NASDAQ:INSM) Files An 8-K Regulation FD Disclosure
ITEM 7.01 — Regulation FD Disclosure.

Story continues below

As previously announced,Insmed Incorporated (the “Company”) will present at the Leerink Partners 7th Annual Global Healthcare Conference in New York on Wednesday, February14, 2018 and a live webcast of the event will be available through the investor relations section of the Company’s website. The slide presentation to be used by the Company during the conference is attached hereto as Exhibit99.1 and incorporated herein by reference.

The information in this Current Report on Form8-K shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01 – Financial Statements and Exhibits.


Exhibit No.



Insmed Incorporated Investor Presentation, dated February14, 2018.

INSMED Inc Exhibit
EX-99.1 2 a18-6034_1ex99d1.htm EX-99.1 Exhibit 99.1 INVESTOR PRESENTATION   Safe Harbor Statement 2 This presentation contains forward looking statements. "Forward-looking statements,…
To view the full exhibit click here


Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company’s lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. The Company’s earlier stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil, a vasodilator of pulmonary arterial vascular beds. The Company is conducting a global Phase III clinical study of ARIKAYCE (the 212 or CONVERT study) in adult patients with NTM lung disease caused by Mycobacterium avium complex (MAC), the infective species in NTM lung disease in the United States, Europe and Japan.

An ad to help with our costs